Minimally invasive glaucoma surgery, or MIGS, is gaining popularity in the United States. Glaucoma, one of the leading causes of blindness in the United States, currently has no cure. The goal of glaucoma treatment is to lower the intraocular pressure to a level that does not do further damage to the optic nerve.
Glaucoma drops, the traditional initial treatment for glaucoma, may not be the best and safest treatment method. There are several reasons for this:
- Low success rate. Many studies have found that only half of glaucoma patients use their eye drops as directed. Why are drops still the first and second line of therapy for this disease? It may be time to consider other options. In Europe, glaucoma surgery is emerging as an initial treatment. With the safety and success rate of MIGS, patients can have confidence in modern procedures. Eye drops were first line therapy in the 1970s and 1980s because surgical therapy was risky and prone to failure, but surgical procedures and outcomes are improving.
- Efficiency of other procedures. Many surgical procedures for glaucoma can be performed in conjunction with cataract surgery to offer treatment for two eye diseases while only going under the knife once. This is both cost-effective and efficient. Procedures can be customized to fit the surgeon’s skill set and the patient’s need, they are FDA approved, and they only add a few extra minutes to cataract removal.
MIGS is low risk with high rewards. With a micro incision, two eye conditions can be treated at once to dramatically improve vision. Glaucoma drops may be the best solution for some patients, but not all. Talk to your doctor about the benefits of MIGS. It may be the solution that you have been waiting for.